These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35938177)

  • 1. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
    Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
    J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
    Starling CT; Messer AA; Kleiman A; McQuade JL; Glitza IC; Torres-Cabala CA; Heberton M
    Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
    Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
    [No Abstract]   [Full Text] [Related]  

  • 5. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
    Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature.
    Piña Y; Evernden BR; Khushalani N; Margolin K; Tawbi H; Tran ND; Macaulay R; Forsyth P; Peguero E
    SAGE Open Med Case Rep; 2021; 9():2050313X211042215. PubMed ID: 34457306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
    Cao Y; Afzal MZ; Shirai K
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
    Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
    JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report.
    Taillefer VT; Pigeon M; Chen M; Larochelle C; Florescu M; Bélanger K; Adam JP
    J Oncol Pharm Pract; 2020 Sep; 26(6):1538-1543. PubMed ID: 32063105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.
    Tauber M; Cohen R; Laly P; Josselin L; André T; Mekinian A
    Clin Rheumatol; 2019 Feb; 38(2):601-602. PubMed ID: 30456528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced seronegative encephalitis.
    Cabral G; Ladeira F; Gil N
    J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D; Frankel AE
    J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab/nivolumab-induced pseudolymphoma in a patient with malignant melanoma.
    Ayoubi N; Haque A; Vera N; Ma S; Messina J; Khushalani N; Seminario-Vidal L
    J Cutan Pathol; 2020 Apr; 47(4):390-393. PubMed ID: 31677178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.